CureVac N.V.

NASDAQ:CVAC   3:59:57 PM EDT
7.23
+0.25 (+3.58%)
Earnings Announcements

Curevac Q3 Pre-Tax Loss Of EUR 47.7 Million

Published: 11/16/2022 12:40 GMT
CureVac N.V. (CVAC) - Eqs-news: Curevac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update.
Curevac NV - Phase 1 Studies in Influenza and Covid-19 on Track to Deliver Clinical Data in Q1 2023.
Curevac NV - Two Proof-of-principle Studies Planned in 2023 to Validate and Optimize Second-generation Mrna Backbone in Oncology.
Curevac NV - Phase 1 Expansion Study of Non-coding Rna-based Candidate Cv8102 Confirms Safety and Strong Immuno-modulatory Characteristics.
Curevac NV - Revenues Amounted to EUR 11.2 Million and EUR 55.7 Million for Three and Nine Months Ended September 30, 2022.
Curevac NV - Operating Loss Amounted to EUR 52.4 Million and EUR 127.9 Million for Three and Nine Months Ended September 30, 2022.
Curevac NV - Pre-tax Loss Was EUR 47.7 Million and EUR 120.4 Million for Three and Nine Months Ended September 30, 2022.
Revenue is expected to be $17.35 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.